Stoxline.com

Stock Symbol:   

Stoxline Mobile
Home  |  Stock Charts  |  Showcases  |  Stock Ranks  |  Options  |  ETFs  |  Educations  |  Forex Crypto

Novartis AG (NVS)

91.73   0.99 (1.09%) 12-07 16:00
Open: 91.68 Pre. Close: 90.74
High: 92.01 Low: 91.16
Volume: 1,801,412 Market Cap: 197,311(M)

Technical analysis

as of: 2022-12-07 4:24:32 PM
Overall:       
Stoxline posted a NEUTRAL today, same as yesterday. Current trend continues, but could change at anytime. It is not a good time to buy or sell.
Target: Six months: 107.46     One year: 125.52
Support: Support1: 84.43    Support2: 79.75
Resistance: Resistance1: 92.01    Resistance2: 107.46
Pivot: 88
Moving Average: MA(5): 90.65     MA(20): 86.97
MA(100): 82.32     MA(250): 85.02
MACD: MACD(12,26): 2.6     Signal(9): 2.3
Stochastic oscillator: %K(14,3): 95.4     %D(3): 96.2
RSI: RSI(14): 80.4
52-week: High: 94.26  Low: 74.08
Average Vol(K): 3-Month: 2,293 (K)  10-Days: 1,630 (K)

Price, moving averages and Bollinger Bands

Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and NEUTRAL in mid-long term.
[ NVS ] has closed below upper band by 11.5%. Bollinger Bands are 59.8% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 5 days. This is a sign that the current trend might continue.

Stock Price Prediction

Update at 5:00pm EST
If tomorrow: Open lower Open higher
High: 92.11 - 92.48 92.48 - 92.79
Low: 90.14 - 90.59 90.59 - 90.99
Close: 90.96 - 91.7 91.7 - 92.33

Company Description

Novartis AG researches, develops, manufactures, and markets healthcare products worldwide. The company operates through two segments, Innovative Medicines and Sandoz. The Innovative Medicines segment offers prescription medicines for patients and healthcare providers. It also provides ophthalmology, neuroscience, immunology, hepatology, dermatology, respiratory, cardiovascular, renal, and metabolism medicine products. The Sandoz segment develops, manufactures, and markets finished dosage form medicines; active ingredients and finished dosage forms of small molecule pharmaceuticals to third parties; and retail generics and anti-infectives. It also provides active pharmaceutical ingredients and intermediates primarily antibiotics; protein- or other biotechnology-based products, including biosimilars; and biotechnology manufacturing services. Novartis AG has a license and collaboration agreement with Alnylam Pharmaceuticals to develop, manufacture, and commercialize inclisiran; and a clinical collaboration with Kura Oncology, Inc. to evaluate the combination of Tipifarnib and Alpelisib in patients with head and neck squamous cell carcinoma. The company was incorporated in 1996 and is headquartered in Basel, Switzerland.

Headline News

Wed, 07 Dec 2022
MorphoSys Inks Licensing Agreement With Novartis For Preclinical Cancer Programs - Yahoo Finance

Wed, 07 Dec 2022
Novartis' Kisqali Prolongs Progression Free Survival Benefit In Metastatic Breast Cancer Versus Chemo - Yahoo Finance

Mon, 05 Dec 2022
Novartis' (NVS) Pluvicto Meets Goal in 2nd Prostate Cancer Study - Nasdaq

Wed, 30 Nov 2022
Should You Add Novartis AG (NVS) Stock to Your Portfolio Wednesday? - InvestorsObserver

Wed, 30 Nov 2022
NVS TGT PGT 2022 Exam Analysis (28th/29th/30th November): Check Good Attempts & Difficulty Level - Jagran Josh

Fri, 25 Nov 2022
NVS TGT Recruitment 2022: Admit card released; here's how to download - The Indian Express

Financial Analysis

Price to Book Value: Outperform
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings: Outperform
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow: Outperform
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets: Neutral
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity: Neutral
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity: Outperform
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Free Technical Analysis Charts

Stock Basics & Statistics

Exchange:  NYSE
Sector:  Healthcare
Industry:  Drug Manufacturers—General
Shares Out. 2,240 (M)
Shares Float 2,080 (M)
% Held by Insiders 0 (%)
% Held by Institutions 9.1 (%)
Shares Short 6,080 (K)
Shares Short P.Month 5,590 (K)

Stock Financials

EPS 3.48
EPS Est Next Qtl 1.27
EPS Est This Year 4.75
EPS Est Next Year 5.25
Book Value (p.s.) 22.5
Profit Margin (%) 41.7
Operating Margin (%) 20.9
Return on Assets (ttm) 5.7
Return on Equity (ttm) 36.9
Qtrly Rev. Growth -4
Gross Profit (p.s.) 16.71
Sales Per Share 23.33
EBITDA (p.s.) 7.18
Qtrly Earnings Growth -41
Operating Cash Flow 14,010 (M)
Levered Free Cash Flow 10,900 (M)

Stock Valuations

PE Ratio 26.36
PEG Ratio 3.6
Price to Book value 4.07
Price to Sales 3.93
Price to Cash Flow 14.66

Stock Dividends

Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date 2021-03-14
Ex-Dividend Date 2021-03-03
Your Ad Here
android_stock_chart
StockChart iOS
stoxline_lite
StoxlineLite iOS
stoxline_pro
StoxlineLite iOS
Option_Calculator
OptionCalc iOS
android_stock_chart
StockChart Android
stoxline_lite
StoxlineLite Android
stoxline_pro
StoxlinePro Android
Option_Calculator
OptionCalc Android
(c) 2006-2022 Stoxline.com | Contact us           
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither Stoxline.com nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the Stoxline.com web site, a user agrees not to redistribute the information found therein.